Ohcanbohtosat - Udo Bonnet
- Čájehuvvo 1 - 6 / 6
-
1
Moclobemide: Therapeutic Use and Clinical Studies Dahkki Udo Bonnet
Almmustuhtton 2003Revisão -
2
The cannabis withdrawal syndrome: current insights Dahkki Udo Bonnet, Ulrich W. Preuss
Almmustuhtton 2017Revisão -
3
ON THE ADDICTIVE POWER OF GABAPENTINOIDS: A MINI-REVIEW Dahkki Udo Bonnet, Emily-Lisa Richter, Katrin Isbruch, Norbert Scherbaum
Almmustuhtton 2018Revisão -
4
Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth Dahkki Heath B. McAnally, Udo Bonnet, Alan D. Kaye
Almmustuhtton 2020Revisão -
5
Risks Associated With the Non-Medicinal Use of Cannabis Dahkki Eva Hoch, Udo Bonnet, Rainer Thomasius, Florian Ganzer, Ursula Havemann‐Reinecke, Ulrich W. Preuss
Almmustuhtton 2015Revisão -
6
Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment Dahkki Michael Specka, Thomas Kuhlmann, Jürgen Sawazki, Udo Bonnet, Renate Steinert, Monika Cybulska-Rycicki, Helmut Eich, Benita Zeiske, Antje Niedersteberg, Luzia Schaaf, Norbert Scherbaum
Almmustuhtton 2020Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Medicine
Psychiatry
Alternative medicine
Pathology
Psychology
Anxiety
Cannabis
Addiction
Cannabidiol
Cannabis Dependence
Craving
Effects of cannabis
Gabapentin
Internal medicine
Pharmacology
Pregabalin
Receptor
Abstinence
Adverse effect
Antidepressant
Atypical depression
Bioinformatics
Biology
Bipolar disorder
Cannabinoid
Clinical psychology
Clomipramine
Context (archaeology)
Designer drug
Detoxification (alternative medicine)